The efficacy and safety of azacitidine in elderly patients (aged >65 years) with myelodysplastic syndromes (MDS) treated outside clinical trials are reported. Thirty-eight patients with MDS received azacitidine (75 mg/m(2), schedule 5+2 +2): seven patients were classified as having refractory cytopenia with multilineage dysplasia (RCMD), nine patients with refractory anemia with excess of blasts (RAEB) type 1, 18 patients with RAEB type 2 and four patients with chronic myelomonocytic leukemia type 2 (CMML-2). According to International Working Group (IWG) 2006 criteria, after the first four cycles we detected complete remission in seven patients (CR, 18%), improvement of bone marrow dysplasia and reduction of blast percentage in seven patients (partial response, 18%), stable disease in 20 patients (53%) and progression to acute leukemia in four patients (10%). Median overall survival for all patients treated was 16.4 months. Only mild non-hematologic toxicity was detected (grade 1-2 nausea and pruritus), whereas 55% of patients experienced hematologic side effects (25% grade 3-4 thrombocytopenia and 30% grade 3-4 neutropenia). Our results suggest that advanced age should not preclude effective treatment with azacitidine in non-selected elderly patients wih MDS.

5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials / Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Petrucci, L; Mancini, M; Alimena, Giuliana. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 53:8(2012), pp. 1558-1560. [10.3109/10428194.2012.660632]

5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.

Breccia M;Serrao A;Petrucci L;ALIMENA, Giuliana
2012

Abstract

The efficacy and safety of azacitidine in elderly patients (aged >65 years) with myelodysplastic syndromes (MDS) treated outside clinical trials are reported. Thirty-eight patients with MDS received azacitidine (75 mg/m(2), schedule 5+2 +2): seven patients were classified as having refractory cytopenia with multilineage dysplasia (RCMD), nine patients with refractory anemia with excess of blasts (RAEB) type 1, 18 patients with RAEB type 2 and four patients with chronic myelomonocytic leukemia type 2 (CMML-2). According to International Working Group (IWG) 2006 criteria, after the first four cycles we detected complete remission in seven patients (CR, 18%), improvement of bone marrow dysplasia and reduction of blast percentage in seven patients (partial response, 18%), stable disease in 20 patients (53%) and progression to acute leukemia in four patients (10%). Median overall survival for all patients treated was 16.4 months. Only mild non-hematologic toxicity was detected (grade 1-2 nausea and pruritus), whereas 55% of patients experienced hematologic side effects (25% grade 3-4 thrombocytopenia and 30% grade 3-4 neutropenia). Our results suggest that advanced age should not preclude effective treatment with azacitidine in non-selected elderly patients wih MDS.
2012
Myelodysplastic syndromes; azacitidine; elderly; outcome; safety
01 Pubblicazione su rivista::01a Articolo in rivista
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials / Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Petrucci, L; Mancini, M; Alimena, Giuliana. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 53:8(2012), pp. 1558-1560. [10.3109/10428194.2012.660632]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/459436
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact